title: Genetic polymorphisms of interleukin-1 beta (IL-1B) and IL-1 receptor antagonist (IL-1RN) and breast cancer risk in Korean women.
abstract: OBJECTIVE
  To evaluate the potential role of genetic polymorphisms of interleukin-1 beta (IL-1B) and IL-1 receptor antagonist (IL-1RN) on breast cancer development, a hospital-based case-control study was conducted in Korea.
  
  
  METHODS
  Histologically confirmed breast cancer cases (n = 560) and controls (n = 509) without cancer history were recruited from three teaching hospitals in Seoul between September 1998 and January 2002. Information on risk factors of breast cancer were collected by interviewed questionnaire. Genotypes of IL-1B (-31C/T) and IL-1RN (86 bp variable number tandom repeats in intron 2) were determined by PCR-CTPP (confronting two-pair primers) and PCR, respectively. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by unconditional logistic regression model.
  
  
  RESULTS
  The IL-1RN *2-allele was associated with decreased breast cancer risk with marginal significance (OR = 0.7, 95% CI = 0.48-1.05). The IL-1B CC or TC genotype was not associated with decreased risk of breast cancer (OR = 0.9, 95% CI = 0.65-1.16). However, combination of IL-1B C-allele (CT or CC) and IL-1RN *2-allele containing genotypes significantly decreased the risk of breast cancer (OR = 0.6, 95% CI = 0.39-0.99). A moderately decreasing trend of risk was observed as the number of 'putative low risk' allele increased (p for trend = 0.07). Suggestive combined effect on breast cancer risk was also observed between body mass index (BMI) and IL-1RN non-*2 allele: women with higher BMI and IL-1RN non-*2 allele had 1.7-fold higher risk than women with lower BMI and IL-1RN*2 genotypes.
  
  
  CONCLUSIONS
  Our results suggest that genetic polymorphisms of interleukin-1 may play a role in the individual susceptibility for breast cancer development in Korean women.
authors.affiliation: Cancer Research Institute, Institute of Environmental Medicine, SNUMRC, and Department of Preventive Medicine, Seoul National University College of Medicine, 28 Yongon-Dong, Chongno-Gu, Seoul, Korea.
authors.forename: Kyoung-Mu
authors.initials: KM
authors.lastname: Lee
authors.forename: Sue Kyung
authors.initials: SK
authors.lastname: Park
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Hamajima
authors.forename: Kazuo
authors.initials: K
authors.lastname: Tajima
authors.forename: Ji-Yeob
authors.initials: JY
authors.lastname: Choi
authors.forename: Dong-Young
authors.initials: DY
authors.lastname: Noh
authors.forename: Sei-Hyun
authors.initials: SH
authors.lastname: Ahn
authors.forename: Keun-Young
authors.initials: KY
authors.lastname: Yoo
authors.forename: Ari
authors.initials: A
authors.lastname: Hirvonen
authors.forename: Daehee
authors.initials: D
authors.lastname: Kang
mesh_terms: D044466:Asian People / Q000235:genetics*; D001943:Breast Neoplasms / Q000209:etiology / Q000235:genetics*; D016022:Case-Control Studies; D017931:DNA Primers; D005260:Female; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000235:genetics*; D007375:Interleukin-1 / Q000235:genetics*; D007723:Korea; D008593:Menopause; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D012307:Risk Factors
chemical_list: D017931:DNA Primers; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1